Clinical-stage biopharmaceutical company Relypsa has finished enrolling patients with chronic kidney disease (CKD) in a pivotal Phase III programme of patiromer for the treatment of hyperkalemia.

Patiromer (RLY5016) for oral suspension is a high-capacity non-absorbed oral potassium binder that the company is developing for the management of elevated serum potassium levels.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The Phase III trial is a two-part study being conducted under an agreed special protocol assessment (SPA) with the US FDA.

Relypsa president Dr Gerrit Klaerner said the rapid enrolment marks patiromer’s potential in fulfilling a significant medical need and that nephrologists are embracing the concept of a novel, chronic treatment of hyperkalemia.

"Completing enrolment of our pivotal programme is a significant milestone that allows Relypsa to ramp up preparations to seek NDA approval and for commercial launch," Klaerner said.

"Patiromer (RLY5016) for oral suspension is a high-capacity non-absorbed oral potassium binder that the company is developing for the management of elevated serum potassium levels."

Part A of the study will be conducted in 240 patients with CKD and hyperkalemia.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Change in serum potassium from baseline to week four after treatment with patiromer is the primary endpoint of the patiromer treatment phase of the single-blind, single-arm trial.

Subjects responding to treatment in Part A will enter into the withdrawal phase of the study, Part B, which is designed to establish the need for chronic treatment with patiromer.

The study will randomise the subjects either to continue on patiromer or to receive placebo for eight more weeks.

The Part B analysis will establish the difference in the change in serum potassium from baseline to week four.

Top-line results from the study are expected in the latter half of 2013.